Anti-HER3 Antibody Combination Therapy for HER2-Normal Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies targeting HER2 and HER3 receptors often show limited efficacy, particularly in HER2-normal cancers and those with low to medium tumor growth inhibition when administered alone.
Innovation Solution
A combination therapy using an anti-HER3 antibody, characterized by specific glycosylation and variable domain sequences, is employed in conjunction with antibodies that bind to HER2 or HER1, inhibiting dimerization and phosphorylation, enhancing tumor growth inhibition in cancers expressing HER3 or HER1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single antibody therapy targeting HER2 or HER3 is used, then treatment simplicity is maintained, but tumor growth inhibition efficacy is limited
Solution Approach 1:
The patent combines anti-HER2 antibody and anti-HER3 antibody into a single composition for simultaneous administration. This merging approach achieves synergistic tumor growth inhibition efficacy (overcoming the limited efficacy of single antibody therapy) while maintaining relative treatment simplicity (as both antibodies are administered together as a unified therapy regimen rather than separate complex protocols).
2Reliability
If combination therapy with multiple antibodies is used, then tumor growth inhibition efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The patent formulates anti-HER2 antibody and anti-HER3 antibody in a single composition for simultaneous administration. This approach enhances tumor growth inhibition efficacy through synergistic action of both antibodies while simplifying treatment administration (reducing the burden of separate administrations and coordinating multiple therapies).
Solution Approach 2:
The combination composition serves multiple therapeutic functions simultaneously: it targets both HER2 and HER3 receptors, provides synergistic anti-tumor activity, and simplifies administration protocols. This multi-functionality resolves the contradiction by making the complex combination therapy as easy to administer as a single therapy would be.
3Reliability
If HER2-targeted therapy is used in HER2-normal cancers, then treatment specificity is maintained, but therapeutic effectiveness is reduced
Solution Approach 1:
The patent changes the therapeutic parameter from HER2-targeted monotherapy to dual-targeted combination therapy (HER2 + HER3). This parameter change enables effective treatment of HER2-normal cancers by targeting HER3, which is overexpressed in these cancers, thereby expanding adaptability to HER2-normal cancers while maintaining high therapeutic effectiveness through synergistic inhibition.
Solution Approach 2:
The patent creates a composite therapeutic approach combining anti-HER2 antibody and anti-HER3 antibody. This composite therapy expands applicability to HER2-normal cancers (where HER3 is the primary target) while maintaining therapeutic effectiveness through the combined action of both antibodies, resolving the contradiction between specificity and effectiveness.
Data Source
AI summary
The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies.